Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Research & Development is the aggregate amount of research and development expenses during the year. Kaken Pharmaceutical Co's Research & Development for the
three
months ended in Mar. 2026 was 円4,940 Mil.
Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円20,585 Mil.
Kaken Pharmaceutical Co (TSE:4521) Research & Development Explanation
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Kaken Pharmaceutical Co Research & Development Related Terms
Kaken Pharmaceutical Co Research & Development Historical Data
* Premium members only.
The historical data trend for Kaken Pharmaceutical Co's Research & Development can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co Research & Development Chart
Kaken Pharmaceutical Co Research & Development Calculation
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円20,585 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Research & Development of 円20,585 Mil mean?
Kaken Pharmaceutical Co (TSE:4521) has a Research & Development of 円20,585 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Kaken Pharmaceutical Co and its competitors.
Is Kaken Pharmaceutical Co's Research & Development too high?
Kaken Pharmaceutical Co's current Research & Development is 円20,585 Mil. Overall, Kaken Pharmaceutical Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Research & Development compare to ZTS and UTHR?
Kaken Pharmaceutical Co's Research & Development of 円20,585 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Kaken Pharmaceutical Co and its competitors. Kaken Pharmaceutical Co's current Research & Development is 円20,585 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co (TSE:4521) is currently considered Fairly Valued. The stock's GF Value™ is 円3,775.44, compared to a current price of 円3,900.00 — trading 3.3% above its estimated fair value. The current Research & Development is 円20,585 Mil. Kaken Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Kaken Pharmaceutical Co (TSE:4521), the current Research & Development is 円20,585 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (TSE:4521) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,900.00 is trading 3.3% above its estimated GF Value™ of 円3,775.44.
GuruFocus considers Kaken Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4521:
Research & Development: 円20,585 Mil
GF Value™: 円3,775.44 vs. price of 円3,900.00 (3.3% above fair value)
No single metric tells the full story. See the TSE:4521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for TSE:4521
Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4521 has been successfully added to your 
